SCHEMBL1650366

SCHEMBL1650366

COc1cc(O)cc(CO)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CALM1 P0DP23 5/20 0.61
PTGS2 P35354 2/20 0.59
ACHE P22303 1/20 0.58
GABRA1 P14867 1/20 0.58
GABRG2 P18507 1/20 0.58
GABRB3 P28472 1/20 0.58
GABRA3 P34903 1/20 0.58
GABRA2 P47869 1/20 0.58
GABRB2 P47870 1/20 0.58
PTPN1 P18031 1/20 0.53
NOS2 P35228 1/20 0.53
AKR1B1 P15121 2/20 0.47
CYP3A4 P08684 2/20 0.46
BACE1 P56817 1/20 0.44
TTR P02766 1/20 0.44
CYP1A1 P04798 1/20 0.44
ALOX5 P09917 1/20 0.44
CYP1B1 Q16678 1/20 0.44
DAO P14920 1/20 0.44
GPBAR1 Q8TDU6 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10536298 1.00 CALM1 (0.61) CALM1PTGS2ACHEGABRA1GABRG2
SCHEMBL29389280 1.00 CALM1 (0.61) CALM1PTGS2ACHEGABRA1GABRG2
SCHEMBL65276 0.86 ALDH1A1 (0.58) CALM1PTGS2ACHEAKR1B1CYP3A4
SCHEMBL1621101 0.86 DAO (0.53) CALM1PTGS2ACHEGABRA1GABRG2
SCHEMBL28123040 0.84 ALDH1A1 (0.55) CALM1PTGS2AKR1B1CYP3A4CYP1A1
SCHEMBL5880258 0.83 PTGS2 (0.65) CALM1PTGS2GABRA1GABRG2GABRB3
SCHEMBL1620230 0.81 GRIN2D (0.47) CALM1PTGS2ACHEGABRA1GABRG2
SCHEMBL30279788 0.81 CALM1 (0.59) CALM1PTGS2GABRA1GABRG2GABRB3
SCHEMBL11941632 0.81 CALM1 (0.59) CALM1PTGS2GABRA1GABRG2GABRB3
SCHEMBL19663703 0.81 CALM1 (0.59) CALM1PTGS2GABRA1GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12459883-B2 Substituted hydroxystilbene compounds and derivatives synthesis and uses thereof Kynan Duke IP, LLC (US) 2025-11-04 US disclosed
WO-2025001407-A1 POLYARYL-CONTAINING MACROCYCLIC COMPOUNDS AND USES THEREOF 浙江养生堂天然药物研究所有限公司 2025-01-02 WO disclosed
US-20230159421-A1 SUBSTITUTED HYDROXYSTILBENE COMPOUNDS AND DERIVATIVES SYNTHESIS AND USES THEREOF Kynan Duke IP, LLC (US) 2023-05-25 US disclosed
US-20230159421-A1 SUBSTITUTED HYDROXYSTILBENE COMPOUNDS AND DERIVATIVES SYNTHESIS AND USES THEREOF Kynan Duke IP, LLC (US) 2023-05-25 US disclosed
CN-115485259-A Substituted hydroxystilbene compounds and derivatives, synthesis and use thereof 凯楠公爵IP有限责任公司 2022-12-16 CN disclosed
WO-2022251191-A1 ONE-COMPONENT DELIVERY SYSTEM FOR NUCLEIC ACIDS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2022-12-01 WO disclosed
CN-114097780-B Method for preparing bactericide for inhibiting botrytis cinerea and application 吉林大学 2022-11-08 CN disclosed
CN-114097780-A Method for preparing bactericide for inhibiting botrytis cinerea and application 吉林大学 2022-03-01 CN disclosed
WO-2021127743-A1 SUBSTITUTED HYDROXYSTILBENE COMPOUNDS AND DERIVATIVES SYNTHESIS AND USES THEREOF Kynan Duke IP, LLC (US) 2021-07-01 WO disclosed
US-10550095-B2 Cancerous cell growth inhibiting compounds WISYS TECHNOLOGY FOUNDATION, INC. (US) 2020-02-04 US disclosed
US-20070292545-A1 ANTI-INFECTIVE AGENTS AND METHODS OF USE WISYS TECHNOLOGY FOUNDATION 2007-12-20 US disclosed
US-20070292545-A1 ANTI-INFECTIVE AGENTS AND METHODS OF USE WISYS TECHNOLOGY FOUNDATION 2007-12-20 US disclosed
US-20070010511-A1 Organic compounds NOVARTIS PHARMA AG (CH) 2007-01-11 US disclosed
EP-1670760-A1 ORGANIC COMPOUNDS Speedel Experimenta AG (CH) 2006-06-21 EP disclosed
WO-2005061457-A1 ORGANIC COMPOUNDS SPEEDEL EXPERIMENTA AG (CH) 2005-07-07 WO disclosed
US-6635655-B1 Agonists or antagonists of peroxisome proliferator-activated receptors AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-10-21 US disclosed
US-6376512-B1 FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-23 US disclosed
US-5059610-A QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1991-10-22 US disclosed
US-4920132-A Quinoline derivatives and use thereof as antagonists of leukotriene D4 RORER PHARMACEUTICAL CORP. (US) 1990-04-24 US disclosed
US-4306083-A Multiphase oxidation of alcohol to aldehyde THE DOW CHEMICAL COMPANY (US) 1981-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010511-A1 Organic compounds REN, ACE, ACE2 CALM1 2312/4885PTGS2 279/4885ACHE 403/4885
US-10550095-B2 Cancerous cell growth inhibiting compounds TYR, MKI67, MC1R CALM1 661/4885PTGS2 284/4885ACHE 3485/4885
US-20070292545-A1 ANTI-INFECTIVE AGENTS AND METHODS OF USE H1-3, H1-0, H1-2 CALM1 2730/4885PTGS2 1061/4885ACHE 150/4885
US-12459883-B2 Substituted hydroxystilbene compounds and derivatives synthesis and uses thereof CYP8B1, HSD11B1, HSD11B2 CALM1 3582/4885PTGS2 213/4885ACHE 3406/4885
US-20230159421-A1 SUBSTITUTED HYDROXYSTILBENE COMPOUNDS AND DERIVATIVES SYNTHESIS AND USES THEREOF CYP8B1, HSD11B1, HSD11B2 CALM1 3582/4885PTGS2 213/4885ACHE 3406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.